Cue Biopharma, Inc.
CUE Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$18.45
KIRA · Stoqly’s AI analyst, in plain words
- Cue Biopharma, Inc. had $27.5M of revenue in fiscal 2025, up 195.7% on the year before. Over five years, revenue changed +54.2% a year on average.
- Its operating margin was −96.7%, up 350.2 pts: of every 100 in sales, about −97 is left after running the business.
- Cue Biopharma, Inc. lost $26.6M in fiscal 2025.
- Free cash flow was −$21.9M in fiscal 2025, −79.6% of revenue.
Market cap
$117M
P/E
—
Revenue
$27.5M
Net income
−$26.6M
Free cash flow
−$21.9M
Operating margin
−96.7%
Cue Biopharma, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+195.7%
Yes. Sales grew 195.7% last year.
Does it make a profit?
−96.9%
No. It lost money last year.
Does profit turn into cash?
−79.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cue Biopharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Cue Biopharma, Inc.
- CIK
- 0001645460
Cue Biopharma, Inc. · CUE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $14.9M | $1.2M | $5.5M | $9.3M | $27.5M |
| Revenue growth | 373.7% | −91.7% | 341.0% | 69.2% | 195.7% |
| Net interest income | $0.0M | −$0.7M | −$1.2M | −$0.8M | −$0.4M |
| Operating margin | −292.6% | −4,275.1% | −949.9% | −446.9% | −96.7% |
| Net income | −$44.2M | −$53.0M | −$50.7M | −$40.7M | −$26.6M |
| Net margin | −295.6% | −4,257.8% | −924.1% | −438.0% | −96.9% |
| Diluted EPS | −$1.41 | −$1.49 | −$1.11 | −$0.72 | −$0.28 |
| Cash | |||||
| Cash from operations | −$38.8M | −$41.8M | −$40.0M | −$36.3M | −$21.7M |
| Capital expenditure | $0.9M | $0.2M | $0.0M | $0.1M | $0.2M |
| Free cash flow | −$39.8M | −$42.0M | −$40.0M | −$36.4M | −$21.9M |
| FCF margin | −266.0% | −3,371.6% | −727.9% | −391.9% | −79.6% |
| Share buybacks | $0.8M | $0.2M | $0.0M | — | — |
| Share count change | 9.1% | 13.9% | 28.3% | 23.1% | 68.2% |
| Debt and strength | |||||
| Cash and short-term investments | $64.4M | $76.3M | $48.5M | $22.5M | $27.1M |
| Debt incl. finance leases | $0.0M | $8.1M | $4.0M | $0.0M | — |
| Shareholders' equity | $65.5M | $65.7M | $37.1M | $17.5M | $26.4M |
| Current ratio | 5.4x | 6.7x | 3.0x | 1.8x | 2.7x |
| Interest coverage | — | −488.3x | −521.5x | −415.0x | −265.5x |
| Returns and quality | |||||
| Return on capital | −3,080.0% | — | — | — | — |
| Return on equity | −61.2% | −80.8% | −98.7% | −149.0% | −121.1% |
| Return on tangible equity | −67.4% | −80.7% | −136.8% | −232.4% | −100.6% |
| Piotroski F-score | 2 | 2 | 3 | 3 | 4 |
| Altman Z'' | −3.0 | −5.5 | −16.4 | −39.7 | −27.3 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$2.4M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cue Biopharma, Inc. · CUE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $18.45 a share, the company is worth $117M.
Source: SEC EDGAR XBRL filings (CIK 0001645460). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.